A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.